PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Clinical trial NCT05053854 · RECRUITING

Trial details

NCT number: NCT05053854
Sponsor: Peter MacCallum Cancer Centre, Australia
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Neuroendocrine Tumors

Start date: 2021-12-08
Primary completion: 2029-06-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.